Evaluation of prescription pattern of antifungal drugs in the dermatology department of a tertiary care teaching hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20231123Keywords:
Antifungal drugs, Prescription pattern, Drug utilization, Essential medicineAbstract
Background: In general, fungal infections are one of the contributors of disease burden in the community, but irrational use of antifungal drugs can result in unwanted adverse events or antifungal drugs resistance. The present study was designed to analyze the prescription pattern of antifungal drugs prescribed in the dermatology department of a tertiary care teaching hospital.
Methods: After getting permission from the ethics committee, this prospective observational cross-sectional study was conducted by analysis of prescriptions of 900 voluntary participant patients over a period of seven months in the dermatology outpatient department of a tertiary care teaching hospital in western India. Prescribed medicines’ parameters were analyzed as per WHO/INRUD prescription indicators.
Results: Overall 900 prescriptions were analyzed, and among them around 50% patients were having tinea corporis and tinea cruris, making it the most common fungal infection. The most commonly prescribed antifungals were Clotrimazole (34.59%), followed by Fluconazole (31.61%) and Luliconazole (23.52%). Percentage of drugs prescribed from the WHO model list of essential medicines was 71.22%. Average number of antifungal drugs per prescription was 2.83 ± 0.57%.
Conclusions: This study indicates prescribing practices of anti-fungal drugs and supportive medicines at tertiary care hospital that can be further improved by promoting prescribing by generic names. Overall final list of essential medicines at district level, state level and national level may vary as compared to the WHO list for anti-fungal drugs and doctors can consider alternative drugs as per domestic resistant pattern.
Metrics
References
Gopimohan P, Sudha MJ, Pillai RT, Ramani PT. A study on the prescription pattern of antifungal drugs in the dermatology department of a tertiary care teaching hospital in Southern Kerala. IJBCP. 2019;8(1):100-3.
De Souza MC, Dos Santos AG, Reis AM. Drug utilization study of systemic antifungal agents in a Brazilian tertiary care hospital. Int J Clin Pharm. 2016;38(6):1398-406.
Pathak AK, Kumar S, Kumar M, Mohan L, Dikshit H. Study of drug utilization pattern for skin diseases in dermatology OPD of an Indian tertiary care hospital - a prescription survey. J Clin Diagn Res. 2016;10(2): FC01-5.
Shetty Y, Brahma S, Sarkate P, Khopkar U, Dandekar S, Dongre M. Prescription audit of anti-fungal treatment of dermatophytoses in the dermatology out patient department of a tertiary care hospital. Biomed Pharm J. 2019;4(2):1-6
Deb P, Mohanty I, Slathia I, Verma V. Drug utilisation and self medication pattern of anti-fungal drugs in dermatology outpatient department of a tertiary care hospital Demographic profile. IJBCP. 2017;6(9):2189-92.
Bansal P, Baishnab S, Singla A. Drug prescribing pattern of antifungal drugs for local fungal infections in a tertiary care hospital: MAMC, Agroha. Int J Basic Clin Pharmacol. 2021;10(6):689.
Vegada BN, Karelia BN, Singh AP. Drug utilization study of antifungal agents used in department of skin & VD of a tertiary care teaching hospital. Int J Pharm Sci Rev Res. 2015;34(1):118-21.
Patil A, Dighe D, Kolte S, Jadhav PR, Deshmukh YA. Drug utilization pattern in dermatology outpatient department at a tertiary care hospital in Navi Mumbai. IJBCP. 2017;6(3):599-62.
Egger M, Hoenigl M, Thompson GR, Carvalho A, Jenks JD. Let’s talk about sex characteristics-As a risk factor for invasive fungal diseases. Mycoses. 2022;65(6):599-612.
WHO model list of essential medicines. Available at: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02. Accessed on 20 November 2022.
ATC/DDD Index 2023. Available at: https://www. whocc, no/atc_ddd_index/. Accessed on 20 November 2022.
Sardana K, Khurana A, IADVL manual on management of Dermatophytosis 1st ed. New Delhi: CBS publisher and distributors; 2018.